Literature DB >> 10102940

Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management.

H J O'Connor1.   

Abstract

A significant proportion of patients with gastro-oesophageal reflux disease (GERD) have Helicobacter pylori infection, but it is unclear whether or not H. pylori should be treated in this clinical setting. The aim of this review was to critically assess the relationship between H. pylori and GERD and its potential implications for the management of GERD. Data for this review were gathered from the following sources up to April 1998-the biomedical database MEDLINE, a detailed review of medical journals, and a review of abstracts submitted to relevant international meetings. On average, 40% of GERD patients carry H. pylori infection, with a reported infection prevalence ranging from 16% to 88%. To date, there has been no reported controlled trial of effective H. pylori therapy in GERD. GERD has been reported to develop de novo following the cure of H. pylori in peptic ulcer disease. In the presence of H. pylori, proton pump inhibitor therapy appears to accelerate the development of atrophic corpus gastritis, a potentially precancerous condition. Conversely, proton pump inhibitor therapy seems to become less effective after cure of H. pylori. The mechanisms underlying these important contrasting phenomena are poorly understood. The relationship between H. pylori and GERD is complex, and it is difficult to give definitive guidelines on the management of H. pylori infection in GERD. Controlled trials of H. pylori therapy in GERD are urgently needed, as well as further long-term data on both the natural history of gastric histopathological changes in the H. pylori-positive GERD patient treated with proton pump inhibitors, and the impact of H. pylori status on the clinical efficacy of antisecretory therapy. Pending these data, it is perhaps advisable to advocate cure of H. pylori in young patients with proton pump inhibitor-dependent GERD who, in the absence of anti-reflux surgery, are faced with the likelihood of long-term medical therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102940     DOI: 10.1046/j.1365-2036.1999.00460.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  15 in total

1.  Gastroesophageal reflux and Helicobacter pylori: a review.

Authors:  F Pace; G Bianchi Porro
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

Review 2.  Treatment of Helicobacter pylori.

Authors:  A Harris
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

Review 3.  The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia.

Authors:  P Malfertheiner; U Peitz
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

4.  Circulating ghrelin levels in patients with various upper gastrointestinal diseases.

Authors:  Hajime Isomoto; Hiroaki Ueno; Yoshito Nishi; Toru Yasutake; Kenji Tanaka; Naoko Kawano; Ken Ohnita; Yohei Mizuta; Kenichiro Inoue; Masamitsu Nakazato; Shigeru Kohno
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

5.  The significance of cagA(+) Helicobacter pylori in reflux oesophagitis.

Authors:  V J Warburton-Timms; A Charlett; R M Valori; J S Uff; N A Shepherd; H Barr; C A McNulty
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

6.  Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis.

Authors:  R L Jaakkimainen; E Boyle; F Tudiver
Journal:  BMJ       Date:  1999-10-16

7.  Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in Western Sydney between 1990 and 1998.

Authors:  H H Xia; N Phung; E Altiparmak; A Berry; M Matheson; N J Talley
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

8.  Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial.

Authors:  J C Y Wu; F K L Chan; J Y L Ching; W-K Leung; Y Hui; R Leong; S C S Chung; J J Y Sung
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

9.  Helicobacter pylori eradication does not exacerbate gastro-oesophageal reflux disease.

Authors:  P Malfertheiner
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

Review 10.  Gastro-oesophageal reflux disease in Asia : birth of a 'new' disease?

Authors:  Ting K Cheung; Benjamin C Y Wong; Shiu K Lam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.